Phillip Broadwith
As Business editor, my aim is to highlight to readers the exciting and innovative chemistry going on in the commercial sector, as well as keeping you abreast of trends and developments in the world of chemistry businesses.
From the point I left school, my aim was to join the pharmaceutical industry. A gap year and summer placements in company labs, and a PhD in organic synthesis followed.
But halfway through my PhD I entered a writing competition run by the Daily Telegraph. I managed to win – somewhat to my own surprise. That changed my perspective and made me think that I should consider writing more seriously as a career. I joined the Royal Society of Chemistry just before submitting my thesis, and luckily a position with Chemistry World came up a few months later. I sometimes miss the thrills (less so the spills) of lab work, but interacting with world-leading scientists and industrialists, as well as learning new things on a daily basis more than makes up for it.
Contact Info
- Email:
- broadwithp@rsc.org
ReviewOrganic Chemistry for Babies
A chance for parents to start training the next generation of chemists
OpinionPushing the limits of patent protection
Some methods of extending exclusivity rights raise legal and ethical questions
OpinionPassing through checkpoints
A new breed of cancer treatments highlights what’s possible when industry concentrates its efforts
OpinionHas Crispr’s patent battle run its course?
As the originators duke it out in court, their patents are becoming increasingly irrelevant
BusinessCompany profile: Ellutia
Ellutia takes GC beyond the ‘box-in-the-lab’, with its customised chromatography
BusinessValeant relinquishes female libido drug
Struggling firm is returning Sprout Pharmaceuticals subsidiary to original shareholders to resolve dispute over marketing
BusinessGenerics firms Amneal and Impax to merge
Deal continues consolidation trend, based on portfolio expansion and simplifying supply chains
BusinessNovartis to buy AAA for radioligand cancer drugs
$3.9bn deal follows European approval of Advanced Accelerator Applications’ first-in-class radionuclide drug Lutathera
OpinionAre trade sanctions fair?
How much should markets be protected from cheaper imports? When does healthy competition become ‘dumping’?
BusinessFederal court quashes Allergan eye drop patents
Ruling negates company’s deal with Mohawk tribe to avoid patent board review
BusinessBASF to buy Bayer seeds and herbicides
€5.9bn sale will help satisfy competition regulators’ worries over Bayer–Monsanto merger
OpinionShould individual companies be blamed for climate change?
Argument ignores consumers’ responsibility driven by our energy demands
BusinessBASF to buy Solvay’s polyamide business
€1.6bn deal covers 2400 employees at sites in Europe, Asia and the Americas
BusinessTeva to sell off women’s health businesses for $1.4bn
Deals continue Teva’s bid to get rid of non-core businesses and raise cash to service its debts
BusinessEli Lilly to cut 3500 jobs
Company will close sites in US and China, and provide incentives for early retirement
OpinionAugmented intelligence
Robots will increasingly work alongside humans to solve complex problems
